Citigroup reiterates rating on Inhibrx Biosciences amid CEO stock purchases
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Citigroup reiterated a market perform rating for Inhibrx Biosciences. Separately, CEO Mark Lappe purchased 10,040 shares of Inhibrx Biosciences stock on October 14, 2026, at an average price of $84.56 per share. This purchase increased his total ownership to 745,588 shares, valued at approximately $63 million.
From dailypolitical.com
Why it matters
The CEO's acquisition of shares suggests internal confidence in the company's valuation. Citigroup's rating maintains a positive outlook on the BioPharma sector, which could influence investor demand for Inhibrx Biosciences stock.
Citigroup previously reiterated a positive rating on the BioPharma sector on October 7, 2026.
From dailypolitical.com
Who's involved
- CitigroupAmerican investment bank that reiterated the market perform rating.
Keep exploring
The entities involved
-
Citigroup
American investment bank and financial services corporation
Related events
- Citigroup restated a buy rating on shares of Intensity Therapeutics.
- Citigroup reiterated a market outperform rating for Alphabet Inc.
- Citigroup reissued a market outperform rating for Applied Digital Corporation on October 15, 2026.
- Citigroup issued a market underperform rating for Hovnanian Enterprises, Inc. on October 22, 2026.
- Citigroup reiterated a market outperform rating for Capital Southwest Corporation.